Lumpipulse G CA19-9-N
Oct 2019
90d
Fujirebio Dianostics, Inc.
1
Total
1
Cleared
0
Denied
Fujirebio Dianostics, Inc. — FDA 510(k) Submissions
Fujirebio Dianostics, Inc. has submitted 1 FDA 510(k) premarket notifications since 2019, of which 1 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer . Use the specialty filter in the sidebar to narrow results.
1 devices